Literature DB >> 3423100

Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol.

S R Jolly1, J N Kipnis, B R Lucchesi.   

Abstract

Verapamil-induced cardiovascular depression has been examined in dial-urethane-anesthetized open chest dogs. Verapamil was administered slowly intravenously until the mean arterial pressure was decreased by approximately 45 mm Hg. The dose of verapamil required to reach the hemodynamic endpoint was 1,495 +/- (SE) 165 micrograms/kg. In a second group, interactions between beta-adrenergic blockade, propranolol 1 mg/kg (i.v.), and verapamil were examined. Although propranolol alone had only minor hemodynamic effects, the cardiac depressant dose of verapamil was reduced significantly to 450 +/- 105 micrograms/kg. After cardiovascular depression with verapamil or verapamil plus propranolol, glucagon was administered to assess its inotropic activity using cumulative doses of 5, 15, and 45 micrograms/kg over 20 min. Glucagon produced a dose-dependent recovery of heart rate, mean arterial pressure, and PR interval. Depressed contractility assessed by peak positive dP/dt and right ventricular isometric contractile force also recovered after glucagon. These results suggest a significant interaction between the potency of verapamil as a myocardial depressant and the state of the myocardium as affected by beta-blockade. Cardiac depression by verapamil or verapamil in combination with propranolol was reversible by glucagon.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3423100     DOI: 10.1159/000138317

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

Review 1.  Management of calcium channel antagonist overdose.

Authors:  Steven D Salhanick; Michael W Shannon
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.